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Objective: This study aimed to explore the incidence and prevalence of OA in the UK in 2017 and their
trends from 1997 to 2017 using a large nationally representative primary care database.
Design: The UK Clinical Practice Research Datalink (CPRD) comprising data on nearly 17.5 million pa-
tients was used for the study. The incidence and prevalence of general practitioner diagnosed OA over a
20 years period (1997e2017) were estimated and age-sex and length of data contribution standardized
using the 2017 CPRD population structure. Cohort effects were examined through Age-period-cohort
analysis.
Results: During 1997e2017, there were 494,716 incident OA cases aged 20 years. The standardised
incidence of any OA in 2017 was 6.8 per 1000 person-years (95% CI 6.7 to 6.9) and prevalence was 10.7%
(95% CI 10.7e10.8%). Both incidence and prevalence were higher in women than men. The incidence of
any-OA decreased gradually in the past 20 years at an annual rate of 1.6% (95%CI -2.0 to 1.1%), and the
reduction speeded up for people born after 1960. The prevalence of any-OA increased gradually at an
annual rate of 1.4% (95% CI 1.3e1.6%). Although the prevalence was highest in Scotland and Northern
Ireland, incidence was highest in the East Midlands. Both incidence and prevalence reported highest in
the knee followed by hip, wrist/hand and ankle/foot.
Conclusion: In the UK approximately one in 10 adults have symptomatic clinically diagnosed OA, the
knee being the commonest. While prevalence has increased and become static after 2008, incidence is
slowly declining. Further research is required to understand these changes.
© 2020 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Osteoarthritis (OA) is one of the commonest long-term condi-
tions, causing significant impairment of physical function. It can
affect several joints which may further compound functional
impairment and participation restriction. In the absence of any
cure, the burden of OA is increasing globally with an estimated 28%
of the older population (>60 years) having OA1. The 2017 Global
Burden of Disease (GBD) report ranked hip and knee OA as the 11th: W. Zhang, Academic Rheu-
ttingham, NG5 1PB, UK.
. Zhang).
r Ltd on behalf of Osteoarthritis Rehighest contributor to global disability and the 23rd highest cause of
disability adjusted life years (DALYs)2. Increasing life expectancy
and the ageing population are expected to make OA the fourth
leading cause of disability by 20203 and a significant increase in
DALYs has already been noted from 2007 to 2017.2
Whilst DALYs provide useful data on disease burden, accurate
information on changing incidence and prevalence of a disease
provides an alternative picture to help guide effective preventive
and management planning. To date, very few studies have exam-
ined trends of OA incidence and prevalence using national repre-
sentative cohort data. The lack of such information creates
challenges in reliable estimation of the burden of OA. Worldwide,
the estimated incidence of OA has varied from a low of 14.6 persearch Society International. This is an open access article under the CC BY license
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years in the UK5. Only three countries have reported increasing
trends of the incidence of OA, whereas none has published preva-
lence trend data. In Sweden, age-standardized hospitalization rates
due to hip and knee OA increased from 1998 to 20146 and in Canada
crude incidence rates increased during 2000e2008 from 11.8 to
14.2 per 1000 person-years in men, and from 15.7 to 18.5 person-
years inwomen4. However, one UK study using the Clinical Practice
Research Datalink (CPRD) reported no change in trends of incidence
of physician-diagnosed OA (1992e2013)5. Seven years of consul-
tation data till 2010 reveals nearly 8.75million people in the UK had
visited any health facility for treatment of OA, and by 2035, 8.3
million people in the UK aged 45 years or over could have symp-
tomatic knee OA.7
Primary care is the usual first point of contact for someone with
symptomatic OA. The UK CPRD is a primary care database that
represents the community burden in better ways than hospital
(secondary care) records and allows evaluation of the trends of
incidence and prevalence over time. However, these estimates
depend on the nature of consultation, the coding system and other
individual factors. While the incidence measures the aetiological
impact of OA, the prevalence measures the disease burden to
inform health resource requirements. Although there have been
some incidence and prevalence studies from the UK5,8,9, they have
given inconsistent results through use of different definitions and
sampling methods. Therefore, the recent trend and natural history
of OA in UK primary care remains largely unknown.
This study aimed to explore both the incidence and prevalence
of OA (overall and joint specific) in the UK during the period 2017
and their trends during 1997e2017 using a large nationally repre-
sentative primary care database.
Methods
This was a descriptive study using longitudinal primary care
database of the UK.
Source population
The CPRD is a large database of general practice electronic
medical records that is generalisable to thewider UK population. As
of 31st December 2017, the CPRD contained data on 17,480,766 in-
dividuals from 736 general practices. Recording of ailment is
mandatory for every visit and there is no limit on the number of
diagnoses entered. The database contains information on symp-
toms, diagnoses, prescriptions, referrals, tests, immunisations, life
style factors, information on medical staff, health promotion ac-
tivities, management and quality outcome framework indicators10.
Substantial research has been undertaken to examine the validity
and completeness of the CPRD and has provided satisfactory re-
sults11. More details about the database can be found at https://
cprd.com/primary-care. This study was approved by the indepen-
dent scientific advisory committee for CPRD research (protocol
reference: 19_030 R). No further ethical permissions were required
for the analyses of these anonymized patient level data.
Study population
CPRD data available for patients registered from 1st January 1997
until 31st December 2017 was used for the study. Inclusion criteria
were individual records with: (1) people aged 20 years or more
during each study year of 1997e2017; (2) active registration for at
least 12 months with the up-to-standard practice prior to the study
start date (determined by CPRD database standards); and (3) data
quality flagged as ‘acceptable’ in the database.Case definition of OA
Incident OAwas defined as the first diagnosis of OA within each
study year. Prevalent OA was defined as having an OA diagnosis by
1st July of each study year. We used Read codes: a medical coding
system of clinical terms used by national health services (NHS),
UK12. The available Read code list (www.keele.ac.uk/mrr) to iden-
tify people with a General Practitioners (GP) diagnosed OA was
adapted according to our inclusion and exclusion criteria. We used
the exact list but excluded two OAs (acromio-clavicular and sterno-
clavicular joints), because of the possible low accuracy of diagnosis
at these joints and the expected incidence is very low. The codes
obtained from the givenwebsite was previously matched with ICD-
10 codes (Musculoskeletal disorder chapter)9. Even though not all
OA joint codes have been validated, a recently published article
shows the positive predictive value (PPV) for Read codes for hip OA
in people aged 60 and over was nearly 80% and suitable for research
purposes13. The Read codes for OA (N05…) used in the study was
further screened by two independent GPs before the use (Appendix
1).
The index date was defined as the date of the first diagnosis of
OA recorded in the database. Patients meeting the following criteria
were excluded from both incidence and prevalence estimation: (1)
any recording of joint diseases (rheumatoid arthritis, psoriatic
arthritis, systemic lupus erythematosus, ankylosing spondylitis,
septic arthritis, spondyloarthropathy or crystal disease and human
parvovirus B19 infection) before or within 3 years after the index
date; (2) any record of specific non-OA diagnosis (soft-tissue dis-
orders, other bone/cartilage diseases) at the same joint in the 12
months before or after the recorded OA consultation; and (3) any
history of joint injury within 1 year prior to the index date. In the
absence of a recording of OA during the study year, any recording of
joint replacement was taken as a proxy measure of OA.
Estimation of incidence and prevalence
The annual incidence rate for OA was defined as the number of
incident (new) OA cases between 1st January and 31st December,
divided by the number of person-years at risk for each calendar
year from 1997 to 2017. Person-years of follow-up were calculated
for eligible people at risk (i.e., no previous diagnosis of OA) from the
latest of 1st January to the earliest date of transfer-out, last data
collection, incident diagnosis of OA, death or 31st December of the
study year. The annual prevalence of OAwas calculated by dividing
the number of people ever diagnosed with OA at 1st July of each
calendar year, by the total number of eligible people in the popu-
lation at the same time point of the calendar year.
Statistical analysis
The incidence and prevalence for each year from 1997 to 2017
were standardised according to age (5 years band), sex and length
of data contribution (observation period) using the CPRD popula-
tion structure in the year 2017 as reference. This method of
adjustment for the observation period has been used previously14.
The length of data contribution of each patient was defined as the
period from the up to standard date for participants to 1st July of
each calendar year for prevalence and 1st January of each calendar
year for incidence. Up to standard date is always later the regis-
tration date. The length of data contribution was then categorised
in four groups 0e3 years, 4e6 years, 7e9 years and  10 years.
Standardization by length of data contribution was done because
higher estimates were observed for longer lengths of data contri-
bution (Supplementary fig S1). For 1997, no data contribution was
seen for  10 years (Supplementary Figs. S1 and S2). Because, even
S. Swain et al. / Osteoarthritis and Cartilage 28 (2020) 792e801794though the first registration datewith the database was traced back
before 1987, the up to standard practice data started recording in
1988, which is acceptable as a quality data, as per CPRD. For sex
specific estimation, only age and length of data contribution
standardisation was done. Age-sex standardized incidence and
prevalence of OA in 2014were calculated for all 13 regions of the UK
and plotted using choropleth maps in QGIS software (V.3, Open
source)15. The prevalence and incidence for the UK region after
2014 could not be estimated adequately because of lack of infor-
mation from the East Midlands region from 2015 onwards.
Age-sex and length of data standardized trends (overall and sex
specific) of the incidence and prevalence of OA were calculated for
any-OA, joint specific and unspecified OA for 1998e2017. Unspec-
ified OA cases are coded as ‘unspecified’ in the database without
any mentioning of the site involved. We computed the incidence
and prevalence across each age group for both sexes only for the
year 2017. The 95% confidence interval (CIs) were derived based on
the assumption of a Poisson distribution for the observed cases. The
trends were tested using Joinpoint regression analysis16 with
Joinpoint software (Version 4.6.0.0)17. Bayesian Information Crite-
rion (BIC) was used to identify the ‘join points’, which describes the
significant change across the trend line and best-fit data series.
Using BIC, a maximum of three joinpoints were selected. Annual
percentage changes (AAPC) for each segment and average AAPC for
the entire study period were calculated at the significance level of
0.05 using the empirical model18. Additional, trend analysis of joint
pain incidence was done using the same database. Details are
provided in Supplementary Fig. S8.
Both incidence and prevalence trends were modelled as a
function of age at diagnosis, period (year of diagnosis) and birth
(year of birth) cohort. To assess the cohort effect, age-period-cohort
(A-P-C) analysis was undertaken19. For visual clarity incidence and
prevalence were aggregated in 5-year age groups for period and
birth cohort graphs. The A-P-C analysis was performed in R using
the package ‘Epi’ and ‘APC’20e22. Statistical analyses wereFig. 1 Age specific incidence (A) and prevalence (B) of OA in 20performed using STATA (SE v 15, STATA corp, Texas) and R(V 5.2, R
software, Austria).23,24Results
Incidence and prevalence
In 2017, the total person-years of follow up for any-OA was
1,495,497 with 10,147 incident OA cases, and the incidence was 6.8
per 1000 person-years (95% CI 6.7 to 6.9 per 1000 person-years).
The incidence was higher in women (8.1; 95% CI 7.9 to 8.3) than in
men (5.5; 95% CI 5.3 to 5.7 per 1000 person-years). The age-specific
incidence in 2017 shows that OA was very rare in people less than
30 years of age. The incidence was 0.08 per 1000 person-years in
both sexes which increased gradually with age and peaked at
75e79 years at 27 per 1000 person-years (95% CI 23.5 to 29.8 per
1000 person-years) in women and 18 per 1000 person-years (95%
CI 15.4 to 20.6 per 1000 person-years) in men [Fig. 1(A)].
Of 1,690,618 eligible individuals in 2017, 181,464 had a recorded
diagnosis of any-OA. The prevalence in 2017 was 10.8% (95% CI:
10.7e10.9%) which was higher in women (12.8%; 95% CI
12.8e12.9%) thanmen (8.6%; 95% CI 8.5e8.7%) across all age groups.
The prevalence increased sharply at age 40e44 years inwomen and
45e49 years in men. In both men and women, the increasing trend
continued until age group of >80 years, reaching the peak of 47% for
women and 35% for men [Fig. 1(B)].
The joint-specific OA incidence (per 1000 person-years) in 2017
was highest for knee (2.3; 95% CI 2.2 to 2.4) followed by hip (1.1;
95% CI 1.1 to 1.2), wrist and hand (0.65; 95% CI 0.6 to 0.7) and ankle
and foot (0.2; 95% CI 0.2 to 0.2). The incidence of unspecified OA
was 5.2 per 1000 person-years (95% CI 5.1 to 5.3). All joint-specific
incidence rates were higher in women than in men. The detailed
distribution across age in both men and women is given in Sup-
plementary Fig. S3. In descending order, the overall prevalence
according to joint site in 2017was; knee (2.9%, 95% CI 2.7e2.9%), hip
(1.5%, 95%CI 1.4e1.5%), wrist or hand (0.5%, 95%CI 0.5e0.5%) and17. OsteoarthritisandCartilage
Year Incidence (per 1000 person-years) Prevalence (%)
Person-Year Cases Crude Incidence
[95% CI]
Age-sex
standardized [95% CI]
Age-sex-LOD
standardized [95% CI]
Eligible
population
Cases Crude
Prevalence [95% CI]
Age-sex
standardized [95% CI]
Age-sex-LOD
standardized [95% CI]
1997 1,321,487 12,296 9.30 [9.14e9.47] 9.17 [9.00e9.34] 5,711,501 195,362 3.42 [3.40e3.44] 6.15 [6.11e6.19]
1998 1,509,159 14,817 9.81 [9.66e9.97] 9.05 [8.89e9.20] 9.50 [7.43e12.67] 5,781,677 215,113 3.72 [3.70e3.74] 7.20 [7.16e7.24] 8.23 [8.06e8.40]
1999 1,831,971 17,216 9.39 [9.26e9.54] 8.87 [8.73e9.01] 9.69 [9.00e10.37] 5,848,216 234,835 4.01 [3.98e4.03] 7.41 [7.37e7.45] 8.47 [8.39e8.55]
2000 2,262,732 20,599 9.10 [8.98e9.22] 8.97 [8.84e9.11] 9.61 [9.31e9.92] 5,896,329 255,264 4.32 [4.30e4.35] 7.41 [7.37e7.44] 8.94 [8.88e9.00]
2001 2,534,401 23,615 9.31 [9.19e9.43] 9.20 [9.07e9.32] 9.36 [9.15e9.57] 5,900,383 276,091 4.77 [4.74e4.80] 7.87 [7.83e7.90] 9.08 [9.03e9.13]
2002 2,858,237 26,597 9.30 [9.19e9.41] 9.37 [9.25e9.49] 9.64 [9.44e9.84] 5,862,771 296,445 5.05 [5.02e5.08] 7.98 [7.95e8.01] 9.27 [9.22e9.32]
2003 3,046,692 29,358 9.63 [9.52e9.74] 9.63 [9.51e9.74] 10.00 [9.81e10.19] 5,788,957 317,611 5.48 [5.45e5.51] 8.19 [8.16e8.22] 9.47 [9.42e9.52]
2004 3,247,175 32,543 10.02 [9.91e10.13] 10.06 [9.95e10.17] 10.42 [10.23e10.61] 5,705,620 339,718 5.95 [5.92e5.98] 8.55 [8.52e8.58] 9.77 [9.73e9.82]
2005 3,317,484 33,093 9.97 [9.86e10.08] 10.15 [10.04e10.26] 10.33 [10.15e10.52] 5,615,033 363,534 6.47 [6.43e6.52] 9.06 [9.03e9.09] 10.21 [10.16e10.26]
2006 3,346,598 30,840 9.21 [9.11e9.31] 9.39 [9.29e9.50] 9.55 [9.37e9.72] 5,467,107 378,799 6.92 [6.90e6.94] 9.44 [9.42e9.47] 10.62 [10.57e10.66]
2007 3,374,993 30,236 8.95 [8.88e9.06] 9.15 [9.04e9.25] 9.49 [9.32e9.65] 5,294,313 388,708 7.34 [7.30e7.38] 9.73 [9.71e9.76] 10.64 [10.60e10.68]
2008 3,381,824 30,261 8.94 [8.84e9.05] 9.20 [9.10e9.30] 9.59 [9.44e9.74] 5,112,496 398,003 7.78 [7.74e7.82] 10.07 [10.04e10.10] 10.91 [10.87e10.95]
2009 3,362,701 29,387 8.73 [8.63e8.83] 8.99 [8.89e9.10] 9.36 [9.22e9.50] 4,924,529 405,402 8.23 [8.20e8.26] 10.35 [10.32e10.38] 10.91 [10.88e10.95]
2010 3,314,620 27,133 8.18 [8.09e8.28] 8.42 [8.32e8.52] 8.74 [8.62e8.87] 4,689,058 403,343 8.60 [8.56e8.64] 10.54 [10.51e10.57] 10.93 [10.90e10.96]
2011 3,235,505 26,100 8.06 [7.96e8.16] 8.30 [8.20e8.40] 8.48 [8.36e8.59] 4,421,201 398,434 9.01 [8.96e9.06] 10.69 [10.66e10.72] 10.94 [10.91e10.97]
2012 3,196,392 24,727 7.73 [7.64e7.83] 7.95 [7.85e8.05] 8.10 [7.90e8.30] 4,165,371 391,691 9.40 [9.36e9.44] 10.76 [10.73e10.79] 10.87 [10.84e10.90]
2013 3,030,317 23,409 7.72 [7.62e7.82] 7.87 [7.77e7.97] 7.94 [7.84e8.05] 3,812,788 374,298 9.82 [9.78e9.86] 10.87 [10.84e10.90] 10.90 [10.87e10.93]
2014 2,758,065 21,113 7.65 [7.55e7.75] 7.74 [7.64e7.85] 7.75 [7.65e7.86] 3,314,992 337,168 10.17 [10.14e10.20] 10.96 [10.93e10.99] 10.95 [10.92e10.98]
2015 2,360,852 17,690 7.49 [7.38e7.60] 7.52 [7.41e7.63] 7.51 [7.40e7.62] 2,761,702 290,020 10.50 [10.47e10.53] 10.94 [10.90e10.97] 10.93 [10.90e10.96]
2016 1,889,587 13,540 7.16 [7.04e7.28] 7.18 [7.06e7.30] 7.17 [7.05e7.29] 2,100,061 223,948 10.66 [10.63e10.69] 10.96 [10.93e11.00] 10.95 [10.92e10.99]
2017 1,495,497 10,146 6.78 [6.67e6.93] 6.78 [6.67e6.93] 6.78 [6.67e6.93] 1,690,618 181,464 10.77 [10.72e10.82] 10.77 [10.72e10.82] 10.77 [10.72e10.82]
AAPC (%) 494,716 1.6[-2.0 to 1.1] 1.4 [1.3 to 1.6]*
Age-sex and length of data contribution (LOD) standardization was done using 2017 CPRD population as standard population. For 1997, LOD standardisation was not calculated because of absence of data for  10 years (See
Supplementary Figs. S1 and S2).
IR: Incidence Rate; CI: Confidence Interval; AAPC: Annual Average Percentage Change; *P-value.
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Fig. 2 Trends of standardized incidence (A) and prevalence (B) between 1998 and 2017. OsteoarthritisandCartilage
S. Swain et al. / Osteoarthritis and Cartilage 28 (2020) 792e801796ankle or foot (0.3%, 95% CI 0.3e0.3%). The prevalence of unspecified
OA was 7.6% (95%CI 7.5e7.6%). The distribution of joint site and
unspecified OA across the sex is provided in Supplementary Fig. S4.
Temporal trends of incidence and prevalence
The incidence (both crude and standardised) of any OA
decreased over time during the study period, changing from 9.5 per
1000 person-years (95% CI 9.4 to 9.7 per 1000 person-years) to 6.8
per 1000 person-years (95% CI 6.7 to 6.9 per 1000 person-years)
(Table I). Similar trends were seen in both women and men
[Fig. 2(A)]. The incidence of OA in men declined from 8.0 per 1000
person-years (95% CI 7.8 to 8.3 per 1000 person-years) in 1997 to
5.5 per 1000 person-years (95% CI 5.3 to 5.7 per 1000 person-years)
in 2017, whereas in women the incidence reduced from 11.5 perFig. 3 Geographic variations in the incidence (A) and prevalence1000 person-years (95% CI 11.2 to 11.7 per 1000 person-years) to 8.1
per 1000 person-years (95%CI 7.9 to 8.3 per 1000 person-years).
Joinpoint analysis identified two points of changes in overall trend
at 2002 and 2005. The AAPC was 1.6% (95% CI -2.0 to 1.1%),
indicating a slight decline in the incidence since 1998. Women
(1.9.1%; 95% CI -2.2 to 1.6%) had a higher decline in rates
compared to men (1.5%; 1.1 to 1.9%). No change in trend was
observed for ankle and foot and wrist and hand sites. Whereas,
unspecified OA trend was on decline, while OA at knee and hip
showed slightly increasing trend. Details of joint specific incidence
trends are given in Supplementary Fig. S5 and sex wise distribution
is given in supplementary table S1.
In contrast, prevalence increased from 1998 to 2017 (Table I).
The age and length of data standardised rates were found to rise in
both men and women across the years. The overall prevalence of(B) of OA in the UK in 2014. OsteoarthritisandCartilage
S. Swain et al. / Osteoarthritis and Cartilage 28 (2020) 792e801 797people with any OA in 2017 was found to increase to 10.7% from
8.2% in 1998, 1.3 times increase in prevalence over this period
[Fig. 2(B)]. The average annual percentage change was 1.4% (95% CI
1.3e1.6%) for any OA, whereas among women it was a 1.6% (95% CI
1.4e1.8%) and in men a 1.3% (95% CI 1.1e1.4%) change each year. The
prevalence of OA in joint-specific OA in 2017 also increased from
1998 except for ankle and foot. Details are given in Supplementary
Fig. S6 and sex wise distribution is given in supplementary table S2.
The additional analysis on trends of incidence of joint pain recorded
in the CPRD shows a sudden increase in the trends after 2003
(Supplementary Fig. S8).Geographic distribution
In 2014, the East Midlands and the North East had the highest
incidence rates of OA of 12.6 per 1000 person-years and 11.7 per
1000 person-years respectively. Lowest incidence rates were seen
in Northern Ireland and South East England [Fig. 3(A)]. The preva-
lence of any OA varied from one region to another within the UK. In
2014 the highest age and sex standardised prevalence were in
Scotland, West Midlands and Northern Ireland ranging from 7% to
9%. The prevalence ranged from 3% to 5% in the Southern region
[Fig. 3(B)].Cohort effects
The incidence was found to decline according to the birth co-
horts. For people in the same age group, those born later were less
likely to have OA than those born earlier (Fig. 4). The reduction
speeded up gradually after 1960, particularly for people aged
20e40 years, suggesting a potential aetiological change after 1960
that led to people being less likely to develop OA. In contrast,
prevalence increased gradually by age but remained almost con-
stant for people born after 1960. The plot of distribution of inci-
dence and prevalence across the age groups for different periods of
birth is provided as supplementary material (Supplementary
Figs. S7(A) & S7(B)).Fig. 4 Age-period-cohort analysis of trend of OA (1997e2017) inDiscussion
This study confirms a high burden of OA in the UKwith a current
(year 2017) prevalence of 10.7% and incidence of 6.8 per 1000
person-years in people aged 20 and over. The prevalence of OA has
increased at a rate of 1.4% per year since 1998, whereas the inci-
dence is declining at a rate of 1.6% per year. Geographically, the
prevalence and incidence of OA are not uniformly distributed.
Scotland, Northern Ireland and West Midlands had higher preva-
lence compared to the rest of the country, whereas, the incidence
was higher in East midlands and North-Eastern regions.
The standardised incidence of OA in 2013 estimated from CPRD
among people aged 45 years or more was 6.3 per 1000 person-
years5. In another study, Yu et al. reported the standardised rates of
any OA incidence in 2010 as 8.6 per 1000 person-years among
persons aged 15 years or more in a UK regional administrative
database25. According to the literature, the prevalence of OA among
people aged 45 years and over varies between 20% and 35%26,27. Our
estimated prevalence among people aged 45 years or more using
the entire CPRD database was nearly 23%. Global burden of disease
reports the prevalence of knee and hip was 7.3% and musculo-
skeletal disease profile report from the NHS shows the prevalence
in 2015e16 was nearly 12%2,28. Comparing the incidence and
prevalence across studies is very difficult because of the wide dif-
ferences in study population, case definition, database quality and
standardisation methods4,27,29. Values similar to our prevalence
estimates have been reported in the UK by Jordan et al.30 using a
database with better recording pattern, as the GPs from this region
actively participate in musculoskeletal research.31
These differences should not affect comparisons within the
study such as, incidence by age and sex. The increase in incidence
and prevalence of OA with age and in women supports existing
epidemiological evidence32. The sudden rise of both prevalence and
incidence at age of 40 years in women has been explained through
biological sex hormone changes and also has been reported uni-
formly in previous studies33,34. The incidence pattern with age also
concurs with previous studies in the UK and other countries.5,29
In both sexes, the prevalence and incidence of ‘unspecified’ OA
was high compared to reported joint-specific OA, a finding also
reported by Yu et al.25 Such ‘unspecified’ reporting reflects thecidence (A) and prevalence (B) in the UK. OsteoarthritisandCartilage
S. Swain et al. / Osteoarthritis and Cartilage 28 (2020) 792e801798recording pattern in primary care, though whether the term ‘un-
specified’ is a substitute to record multiple joint involvement, re-
mains unclear. The higher burden of knee and hip OA in this study
reflects consultation behaviour, for example a preference to seek
advice for large joint rather than small joint problems. There is
wide variation in reported prevalence of OA at individual joint sites.
Again, this could indicate different methods of ascertainment, and
whether diagnosis is purely clinical or based on presence of
radiographic OA changes. Also the findings are likely to under-
represent true prevalence and incidence, as more than 12% of
people with hip OA never consult GPs about their condition, even if
it is symptomatic.13Trends of incidence and prevalence
Surprisingly, therewas an overall slow decline in incidence rates
for any-OA since 1998. Yu et al. found no change in trends of inci-
dence physician-diagnosed OA for the period 1997e2013 among
people aged 45 years or more5. One other population-based study
in the US found no increase in trends of radiographic knee OA
during the period 1974e1994 after adjusting for body mass index
(BMI) change35. The Joinpoint analysis reveals a slight rise in inci-
dence from 2000 to 2004 followed by a slow decline. We found
significant increase in rate for knee and hip joint-specific incidence,
but the ‘unspecified’ OA rate was declining, indicating possible
improvement in clinical coding. Perhaps the increase in trend of
‘joint-pain’ after the year 2005 partially explains the gap (Supple-
mentary Fig. S6) if physicians became more prone to report
symptoms rather than a specific diagnosis. We observed a nearly
1.3 times increase in standardized prevalence of OA from 1998 to
2017, with an annual percentage increase of 1.4%. Globally, contri-
bution of OA to the total prevalent cases has increased by 8.5% from
1990 to 2017 and in the UK the prevalence has increased from 6.3%
in 1990e7.7% in 20172. The increase in prevalence with the slow
declining incidence rate is surprising. Especially, the increased
prevalence trend could be because of the cumulative nature of the
longitudinal database from electronic health records. CPRD is a
dynamic database with people moving in and out of the database at
any time point, which changes the eligible population every year.
Also, we found the prevalence trend is becoming stable since 2008,
which partially explains the effect of declining incidence.
Age-period-cohort effects, length of data contribution and the
participation of practices in the CPRD database influence the inci-
dence estimates14,30. Our age-period-cohort analysis shows a
strong cohort effect in incidence among people born after the
1960s. It suggests that people born after this periodmay expose less
to physically very demanding occupations such as coal-mining,
farming and certain heavy industrial work because of change in
patterns of occupation in the UK since 1960s including the mining
activities36. We standardised for the length of data contribution
period to eliminate the problem of prevalent cases for OA for robust
incidence estimates. In contrast, prevalence remained almost un-
changed in people born after 1960s (Fig. 4), indicating the treat-
ment of this condition may remain same.Geographical distribution
Scotland and the middle region of England and had higher
incidence rates in 2014 compared to the rest of the UK5. The reasons
for regional variation could be differences in practice areas, socio-
economic conditions, lifestyles and health seeking behaviours.
Interestingly, higher prevalence in the Northern region largelymatches the obesity distribution in the Northern region of the UK
compared to the South.37Limitations of the study
In addition to the highlighted caveats on coding of the diseases
and data contribution, a few more limitations do exist. The case
definition relied on the clinical diagnosis by the general practi-
tioners without requiring demonstration of structural OA on im-
aging. However, concordance between symptoms and radiographic
OA (the usual way to assess structural OA) is variable and often
poor, depending on the joint site being assessed38. Patient-centred
outcomes rather than imaging changes are key determinants of
disability and burden of disease, and the National Institute for
Health and Care Excellence (NICE) recommends that a purely
clinical diagnosis is sufficient and that imaging should be reserved
for specific situations such as atypical clinical features or rapid
progression of symptoms39. Coding of joint specific OA in a
consultation database is always controversial. The index date re-
flects the date of allocation of Read codes for OA and does not
reflect disease onset or the date of diagnosis. However, the date of
allocation of a Read code for OA would be expected to be within a
few months of the date of diagnosis13. We did not perform a vali-
dation study for the OA definitions used in this study, therefore the
results are open to misclassification bias. Caution must be taken
when comparing the prevalence and incidence of this study with
that reported in other studies. However, we believe this will not
affect the internal validity, such as prevalence and incidence by age
and gender, and temporal trends of OA/joint pain in the past 20
years in the UK as they all were based on the same Read codes to
define the disease. Furthermore, because our estimates are based
on GP consultations for symptomatic regional joint pain, and not all
people with symptomatic OA will consult their GP, these data may
underestimate the true community prevalence and incidence of
symptomatic OA. Unlike other chronic conditions, OA is not
included in Quality and Outcome Framework (QOF) by the NHS in
2004. QOF is an incentivising program, which rewards GP practices
in England for quality delivery of primary care including the diag-
nosis and recording of conditions. Therefore, the prevalence and
incidence might have been underestimated. In addition, the
exclusion criteria used in our study might have led to underesti-
mation of the burden. Also, health care accessibility might influ-
ence the estimation. CPRD might have the duplication of people,
because of the movement of patients from one practice area to
other and being recorded with new unique identifier. However, we
assume, the rate of migration might be similar in both OA group
and ‘at-risk’ population. Even though, the method of standardising
by length of data observation has been used previously for calcu-
lating trends using electronic health records, some residual con-
founding by length of data observation might still exist. Another
limitation is the geographical presentation of the estimates, which
needs cautious interpretation because of the non-uniform practices
involved in the database.Conclusion
One in 10 adults aged 20 years or more in the UK has GP-diag-
nosed OA and the knee was the leading site. The incidence of GP-
diagnosed OA is declining, but the prevalence is rising slowly in the
UK. A cohort effect was observed, that is, within the same age
groups people born after 1960s had lower incidence than those
born earlier. If it is a real change in trend or change in recoding and
S. Swain et al. / Osteoarthritis and Cartilage 28 (2020) 792e801 799reporting pattern needs to be studied. Also, further research is
necessary to understand these temporal trends in OA.Read Code Name of the condition
N05zJ00 Osteoarthritis NOS, of hip
N053512 Hip osteoarthitis NOS
N05z511 Hip osteoarthritis NOSContributor and guarantor information
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been omitted.N053500 Localised osteoarthritis, unspecified, pelvic region/thigh
N051500 Localised, primary osteoarthritis of the pelvic region/thigh
N052500 Localised, secondary osteoarthritis of pelvic region/thigh
N054500 Oligoarticular osteoarthritis, unspecified, of pelvis/thigh
N05z500 Osteoarthritis NOS, pelvic region/thigh
Nyu2E11 [X] Unilateral secondary coxarthrosisCompeting interests
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The authors declare that they have no conflict of interest.Nyu2200 [X]Other dysplastic coxarthrosis
Nyu2300 [X]Other post-traumatic coxarthrosis
Nyu2100 [X]Other primary coxarthrosis
Nyu2E00 [X]Other secondary coxarthrosis
Nyu2400 [X]Other secondary coxarthrosis, bilateral
N051900 Primary coxarthrosis, bilateral
N05zL00 Osteoarthritis NOS, of knee
N05z611 Knee osteoarthritis NOS
N053600 Localised osteoarthritis, unspecified, of the lower leg
N05z600 Osteoarthritis NOS, of the lower leg
N051600 Localised, primary osteoarthritis of the lower leg
N052600 Localised, secondary osteoarthritis of the lower leg
N054600 Oligoarticular osteoarthritis, unspecified, of lower legFunding
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of the NHS, the NIHR or the Department of Health and Social Care.N053611 Patellofemoral osteoarthritis
N05zM00 Osteoarthritis NOS, of tibio-fibular joint
Nyu2511 [X] Unilateral primary gonarthrosis
N051B00 Primary gonarthrosis, bilateral
Nyu2811 [X] Unilateral secondary gonarthrosis
Nyu2800 [X]Other secondary gonarthrosis
Nyu2700 [X]Other secondary gonarthrosis, bilateral
Nyu2500 [X]Other primary gonarthrosisRole of the funding sources
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study; collection, management, analysis, and interpretation of the
data; or preparation, review, or approval of the manuscript and the
decision to submit the manuscript for publication.N052C00 Post-traumatic gonarthrosis, unilateral
N05zN00 Osteoarthritis NOS, of ankle
N05z700 Osteoarthritis NOS, of ankle and foot
N05zU00 Osteoarthritis NOS, of IP joint of toe
N05zT00 Osteoarthritis NOS, of lesser MTP joint
N05zS00 Osteoarthritis NOS, of 1st MTP joint
N05zR00 Osteoarthritis NOS, of other tarsal joint
N05zP00 Osteoarthritis NOS, of subtalar jointStudies involving humans or animals
No direct participant recruitment was done for the study. This
study was approved by the independent scientific advisory com-
mittee for CPRD research (protocol reference: 19_030 R).N05z712 Foot Osteoarthritis NOS
N05zQ00 Osteoarthritis NOS, of talonavicular joint
N053700 Localised osteoarthritis, unspecified, of the ankle and foot
N051700 Localised, primary osteoarthritis of the ankle and foot
N051E00 Localised, primary osteoarthritis of toe
N052700 Localised, secondary osteoarthritis of the ankle and foot
N05z713 Toe osteoarthritis NOS
N05z711 Ankle osteoarthritis NOS
N054700 Oligoarticular osteoarthritis, unspecified, of ankle/foot
Nyu2900 [X]Other primary arthrosis of first carpometacarpal jointAcknowledgements
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Nyu2B00 [X]Other 2ndry arthrosis/1st carpometacarpal joints, bilaterl
N053400 Localised osteoarthritis, unspecified, of the hand
N051400 Localised, primary osteoarthritis of the hand
N05011 Heberden's node
N052400 Localised, secondary osteoarthritis of the hand
N05z412 Thumb osteoarthritis NOS
N050700 Heberden's node with arthropathy
N054400 Oligoarticular osteoarthritis, unspecified, of hand
N050112 Bouchard's node
N05zH00 Osteoarthritis NOS, of DIP joint of fingerData sharing statement
We used anonymised data on individual patients on which the
analysis, results, and conclusions reported in the paper are based.
The CPRD data is not distributable under licence. However, the
relevant data can be obtained directly from the agency (https://
www.cprd.com/). The codes developed for the analysis can be
available upon a valid request.N050300 Bouchard's node with arthropathy
N05zG00 Osteoarthritis NOS, of PIP joint of finger
N05z311 Wrist osteoarthritis NOS
N05z400 Osteoarthritis NOS, of the hand
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Read codes for Osteoarthritis
(continued )
Read Code Name of the condition
N051D00 Localised, primary osteoarthritis of the wrist
N05z411 Finger osteoarthritis NOS
N05zE00 Osteoarthritis NOS, of wrist
N05zF00 Osteoarthritis NOS, of MCP joint
N050100 Generalized OA of hand
N06z311 Wrist arthritis NOS
N051800 Localised, primary osteoarthritis of other specified site
N051.00 Localised, primary osteoarthritis
N051z00 Localised, primary osteoarthritis NOS
N051000 Localised, primary osteoarthritis of unspecified site
N052.00 Localised, secondary osteoarthritis
N052z00 Localised, secondary osteoarthritis NOS
N052800 Localised, secondary osteoarthritis of other specified site
N050000 Osteoarthritis and allied disorders
N054.00 Oligoarticular osteoarthritis, unspecified
N054900 Oligoarticular osteoarthritis, unspecified, multiple sites
Nyu2.00 [X]Arthrosis
Nyu2000 [X]Other polyarthrosis
N054000 Oligoarticular osteoarthritis, unspec, of unspecified sites
N05z000 Osteoarthritis NOS, of unspecified site
N05..00 Osteoarthritis and allied disorders
N054800 Oligoarticular osteoarthritis, unspecified, other spec sites
N05z.00 Osteoarthritis NOS
N053z00 Localised osteoarthritis, unspecified, NOS
N053800 Localised osteoarthritis, unspecified, of other spec site
N05zz00 Osteoarthritis NOS
N053000 Localised osteoarthritis, unspecified, of unspecified site
N05..11 Osteoarthritis
N05z800 Osteoarthritis NOS, other specified site
N054z00 Osteoarthritis of more than one site, unspecified, NOS
N06z.11 Arthritis
N050500 Secondary multiple arthrosis
N050400 Primary generalized osteoarthrosis
N050Z00 Generalized OA NOS
N050200 Generalised OA Multiple sites
N050.00 Generalised OA
NOS- ‘not otherwise specified.
We did not include acromio-clavicular and sterno-clavicular joint OA because of
the possible accuracy of diagnosis at these joints and the expected incidence is
very low.
Osteoarthritis
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